Saracatinib

• CAT Number: I003391
• CAS Number: 379231-04-6
• Molecular Formula: C₂₇H₃₂ClN₅O₅
• Molecular Weight: 542.03
• Purity: 98%
• Target: Bcr-Abl
• Solubility: DMSO: ≥ 44 mg/mL
• Storage: 3 years -20C powder
• IC50: 2.7 nM(c-Src); 30 nM (v-Abl)
• InChI: InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
• InChIKey: OUKYUETWWIPKQR-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)CCOC2=CC(=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6

Saracatinib is an orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.

Overview of Clinical Research

Originator AstraZeneca
Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Icahn School of Medicine at Mount Sinai; Innovative Medicines Initiative; Loyola University Chicago; National Center for Advancing Translational Sciences; National Jewish Health; NHS National Services Scotland; Royal National Orthopaedic Hospital; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of Oxford; University of South Florida; VU University Medical Center; Yale University
Class Analgesics; Antidementias; Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
Mechanism of Action Src-Family kinase inhibitors
Orphan Drug Status Yes – Idiopathic pulmonary fibrosis
New Molecular Entity Yes
Available For Licensing Yes

Reference

1. Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28.
Osteoporosis: now and the future.
Rachner TD(1), Khosla S, Hofbauer LC.
DOI: 10.1016/S0140-6736(10)62349-5 PMCID: PMC3555696 PMID: 21450337
Conflict of interest statement: Conflict of interest Tilman Rachner has received reimbursement of travel and accommodation expenses from Novartis. Sundeep Khosla has received honoraria for serving on advisory boards for Bone Therapeutics and Pfizer. Lorenz Hofbauer has received honoraria and speakers fees including reimbursement of travel and accommodation expenses from Amgen, Daiichi Sankyo, Merck, Novartis, Nycomed, and Servier.

2. Pharmazie. 2020 Jul 1;75(7):339-343. doi: 10.1691/ph.2020.9949.
Anti-allergic effect of the Src family kinase inhibitor saracatinib.
Yamaki K(1), Terashi M(2), Ogura S(2), Inoue S(2), Naka N(2), Nakagaki T(2), Oka N(2), Koyama Y(2).
DOI: 10.1691/ph.2020.9949 PMID: 32635977 [

3. Viruses. 2018 May 24;10(6):283. doi: 10.3390/v10060283.
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.
Shin JS(1)(2), Jung E(3), Kim M(4)(5), Baric RS(6), Go YY(7)(8).
DOI: 10.3390/v10060283 PMCID: PMC6024778 PMID: 29795047